Form D · Biotechnology
2seventy bio, Inc.
Cambridge, MA · CIK 0001860782
Offering snapshot reported Mar 31, 2022 · SEC filing
- Reported sold
- $170M Offering amount: $170M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 17, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 31, 2022 | Initial | $170,000,009 | No comparison | 22 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $3.75M
- Finders' fees
- $0
- Form D file number
- 021-439933
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Goldman Sachs & Co. LLC | 361 |
Source: Form D, filed Mar 31, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| William D. Baird | Executive |
| Sarah Js Glickman | Director |
| Philip Gregory | Executive |
| Nicola Heffron | Executive |
| Ramy Ibrahim | Director |
| Nick Leschly | Director, Executive |
| Daniel Lynch | Director |
| Marcela V. Maus | Director |
| William R. Sellers | Director |
| Denice Torres | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
60 Binney Street
Cambridge, MA, 02142
Cambridge, MA, 02142